Prader-willi.pl

Bibliografia
L’Allemand, D., U. Eiholzer, M. Schlumpf, H. Steiner, W. Riesen. 2000. ’Cardiovascular risk factors improve under 3 years of GHT in Prader-Willi syndrome.’ Eur J Pediatr 159: 835-842. Aughton, D. & S. B. Cassidy. 1990. Physical features of Prader-Willi syndrome in neonates.’ Beccaria, L., F. Benzi, A. Sanzari, L. Bossio, P. Brambilla, G. Ghiumello. 1996. ‘Impairment of GH responsiveness to GH releasing hormone and pyridostigmine in patients affected with Prader-Willi syndrome.’ J Endocrinol Invest 19: 687-692. Bideci, A., P. Cinaz, A. Hasanoglu, S. Elbeg. 1997. 'Serum levels of insuline-like growth factor-I and insuline-like growth factor binding protein-3 in obese children.' J Pediatr Endocrinol Metab 10: 295- Brambilla, P., L. Bosio, P. Manzoni, A. Pietrobelli, L. Beccaria, G. Chiumello. 1997. ‘Peculiar body composition in patients with Prader – Labhart – Willi syndrome.’ Am J Bray, G., W. Dahms, R. Swerdloss, R. Fiser, R. Atkinson, X. Carrel. 1983. ‘The Prader-Willi syndrome. A study of 40 patients and a review of the literature.’ Medicine 62: 59-80. Burman, P., M. Ritzen, A. C. Lindgren. 2001. ‘Endocrine disfunction in Prader-Willi syndrome: a review with special reference to GH.’ Endocr Rev 22: 787-799. Butler, M. 'Prader - Willi syndrome: current understanding of cause and diagnosis.' Am J Med Genet Carrel A. L., S. E. Myers, B. Y. Whitman, D. B. Allen.1999. 'Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study'. J Pediatr 134: 215-21. Carrel A. L., D. B. Allen. 2001. 'Prader-Willi syndrome: how does growth hormone affect body composition and physical function?' J Pediatr Endocrinol Metab 14 Suppl 6: 1445-51. Carrel, A. L., S. E. Myers, B. Y. Whitman, D. B. Allen. 2001. 'Sustained benefits of growth hormone on body composition, fat utilization, physical strenght and agility, and growth in Prader - Willi syndrome are dose-dependent.' J Pediatr Endocrinol Metab 14: 1097-1105 Carrel, A. L., V. Moerchen, S. E. Myers, M. T. Bekx, B. Y. Whitman, D. B.Allen. 2004. 'Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.' J Pediatr 145: 744-9. Corrias, A. 2000. 'GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsivness to various provocative stimuli.' J Endocrinol Invest 23: 84-89. Costeff, H., V. A. Holm, R. Ruvalcaba, J. Shaver. 1990. ‘Growth hormone secretion in Prade- Willi syndrome.’ Acta Paediatr Scand 79: 1059-1062. Davies P. S. 1999. 'Body composition in Prader-Willi syndrome: assessment and effects of growth hormone administration.' Acta Paediatr Suppl 88: 105-8. Donaldson, M. D. C., C. E. Chu., A. Cooke, A. Wilson, S. A. Greene, J. B. P. Stevenson. 1994. The Prader-Willi Syndrome. Arch Dis Child 70: 58-63. Dunn, H. G. 1968. 'The Prader-Willi syndrome: review of the literature and report of 9 cases.' Acta Paediatr Scand suppl 186: 1-38. Eiholzer, U., D. l'Allemand. 2000. 'Growth hormone normalises height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy.' Horm Res 53: 185-92. Eiholzer, U. 2001. Prader-Willi syndrome. Effects of human growth hormone treatment. Karger: Basel. Eiholzer, U., K. Stutz, C. Weinmann, T. Torresani, L. Moliari, A.Prader. 1998a. ’Low insulin, IGF-I and IGFBP-3 levels in children with Prader – Labhart – Willi syndrome’. Eur J Pediatr 157: 890-893. Eiholzer, U., R. Gissin, C. Weinmann, S. Kriemler, H. Steinert, T. Torresani, M. Zachmann, A. Prader. 1998b. ’Treatment with human growth hormone in patients with Prader – Labhart – Willi syndrome reduces body fat and increases muscle mass and physical performance.’ Eur Eiholzer, U., D. L'allemand, M. Schlumpf, V. Rousson, T.Gasser, C. Fusch. 2004. 'Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome.' J Pediatr 144: Fesseler, W. H., J. R. Bierich. 1983. ‘Untersuchungen beim Prader – Labhart – Willi syndrom.’ Monatsschr Kinderheilkd 131: 844-847. Greenswag, L. R. 1987. ‘Adults with Preder-Willi syndrome. A survey of 232 cases.’ Dev Med Child Neurol 29: 145-152. Grosso, S., M. Cioni, S. Buoni, L. Peruzzi, L. Pucci, R. Berardi. 1998. 'Growth hormone secretion in Prader-Willi syndrome'. J Endocrinol Invest 21: 418-422. Grugni, G., G. Guzzaloni, D. Moro, D. Bettio, C. De Medici, F. Morabito. 1998. 'Reduced GH responsivness to combined GH releasing hormone and pyridostimine and administration in the Prader-Willi syndrome.' Clin Endocrinol (Oxf) 48: 769-775. Hall, B. D. & D. Smith. 1972. ‘Prader-Willi syndrome’. J Pediatr 81: 286-293. Haqq, A. M., D. D. Stadler, R. H. Jackson, R. G. Rosenfeld, J. Q. Purnell, S. H. LaFranchi. 2003. 'Effects of Growth Hormone on Pulmonary Function, Sleep Quality, Behavior, Cognition, Growth Velocity, Body Composition, and Resting Energy Expenditure in Prader-Willi Syndrome.' The Journal of Clinical Endocrinology & Metabolism 88: 2206-2212. Hoefnagel, D, P. J. Costello, K. Hatoum. 1967. ‘Prader-Willi syndrome.’ J Ment Def Res 11: 1-11 Holm, V., Sulzbacher, S. J. P. P. L. (red.). 1981. The Prader-Willi Syndrome. Baltimore: University Park Press Holm, V. A., S. B. Cassidy, M. G. Butler, J. M. Hanchett, L. R. Grinswag, B. Y. Whitman, F. Greenberg. 1993. ’Prader-Willi syndrome. Consensus diagnostic criteria.’ Pediatrics 91: 398-402. Lee, P. D. 2000. 'Effects of growth hormone treatment in children with Prader-Willi syndrome.' Lindgren, A. C., E. M. Ritzen. 1999. 'Five years of growth hormone treatment in children with Prader-Willi syndrome.' Acta Paediatr Suppl 88: 109-11. Mueller, J. 1997. ’Hypogonadism and Endocrine metabolic disorders in Prader-Willi syndrome.‘ Acta Paediatr Suppl 423: 58-59. Myers, S. E., A. L. Carrel , B.Y.Whitman, D. B.Allen. 2000. 'Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.' J Pediatr 137: 42-9. Nagai, T., M. Mori. 1999. 'Prader-Willi syndrome, diabetes mellitus and hypogonadism. Biomed Obata, K., S. Sakazume, A. Yoshino, N. Murakami, R. Sakuta. 2003. 'Effects of 5 years growth hormone treatment in patients with Prader-Willi syndrome.' J Pediatr Endocrinol Metab 16:155-62. Park, M. J., H. S. Kim, J. H. Kang, D. H. Kim, C. Y. Chung. 1999. 'Serum levels of insulin- like growth factor (IGF)-I, free IGF-I, IGF binding protein (IGFBP)-I, IGFBP-3, and insulin in obese children.' J Pediatr Endocrinol Metab 12: 139-144. Prader, A., A. Labhart, H. Willi. 1956. ’Ein syndrom von Adipositas, Kleinwuhs, Kryptohismus und Oligophrenie nach myotonieartigemzustand im Neugeborenenalter.’ Sweiz Med Wochenschr 86: 1260-1261. Rosenfeld, R. G. et al. 1995. ’Diagnostic controversy: diagnosis of childhood growth hormone deficiency revisited.’ J Clin Endokr Metab 80: 1532-1540. Rubin, K., S. B. Cassidy. 1988. ‘Hypogonadism and Osteoporosis’ w: L. R.Greenswag, R. C. Alexander (red.) Management of Prader – Willi syndrome. New York: Springerverlag. Sacco, M., G. Di Giorgio. 2005. 'Sudden death in Prader-Willi syndrome during growth hormone therapy'. Horm Res 63: 29-32. Salomon, F., R. Cuneo, A. Umpleby, P. Songsen. 1994. 'Interactions of body fat and muscle mass with substrat concentrations and fasting insulin levels in adults with growth hormone deficiency.' Clin Sci (Colh) 87: 201-29-06 Shulman D. I. 2002. 'Metabolic effects of growth hormone in the child and adolescent.' Curr Opin Pediatr 14: 432-6. Tauber, M., C. Barbeau, B. Joured, C. Pienkowski, P. Malzac, A. Moncla, P. Rochiccioli. 2000. ‘Auxological endocrine evolution of 28 children with Prader-Willi syndrome: effect of GH therapy in 14 children.’ Horm Res 53: 279-287. Vahl, N., J. O. Jorgensen, T. B. Hansen, I. B. Klausen, A. G. Jurik, C. Hagen et al. 1998. ’The favorable effects of GH substitution on hypercholesterolaemia in GH deficient adults are not associated with concomitant reductions and adiposity. 12 month and placebo-controlled study’. Int J Obes Relat Metab Disord 22: 529-536 Vanderschueren-Lodeweycks, M. 1993. ’The effects of simple obesity, growth and growth hormone.’ Horm Res 40: 23-30. Vignolo, M., A. Naselli, E. di Battista, M. Mostert, G. Aicardi. 1988. ‘Growth and development in simple obesity’. Eur J Pediatr 147: 242-244. Vliet, G. V., C. L. Deal, P. A. Crock, Y. Robitaille, L. L. Oligny. 2004. 'Sudden death in growth hormone-treated children with Prader-Willi syndrome.' J Pediatr 144: 129-131. Weninger, M., G. Schernthaner, H. Frisch, K. Wildhalm. 1983. ’Endokrine Unterzuchungen bei Prader – Labhart – Willi Syndrom: Pubertaetseintritt bei einem 19 jahre alten Knaben nach Langzeitverabreichung eines LHRH – Analogons.’ Exp Clin Endokrinol 82: 8-14. Whitman, B. Y., S. Myers, A. Carrel, D. Allen. 2002. 'The Behavioral Impact of Growth Hormone Treatment for Children and Adolescents With Prader-Willi Syndrome: A 2- Year, Controlled Study.' Whitman, B., A. Carrel, T. Bekx , C. Weber, D. Allen, S. Myers. 2004. 'Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months.' J Widhalm, K., V. Veitl, K. Irsigler. 1981. Evidence for decreased energy expenditure in Prader – Labhardt – Willi Syndrome: Assesment by means of the Vienna calorimeter. Proc Ind Cong Nutrition. New York. Williams, M. S., B. L. Roneey, J. Williams, K. Josephson, R. Pauli. 1994. ‘Investigation of termoregulatory characteristics in patients with Prader-Willi syndrome.’ Am J Med n Genet 49: 302-327. Wollmann, H. A., U. Schultz, M. Grauer, M. Ranke. 1998. ’Reference values for height and weight in Prader-Willi syndrome based on 315 patients.’ Eur J Pediatr 157: 634-642. Zellweger, H. 1981. ‘Diagnosis and therapy in the first phase of PWS.’ w: Holm, V., Sulzbacher, S. J. P. P. L. (red.) The Prader-Willi Syndrome. Baltimore: University

Source: http://www.prader-willi.pl/pws_fcms/freshcms/admin/ckfinder/files/Bibliografia_Hormon%20wzrostu.pdf